IPO Timeline
Broker Deadline
2024-10-28
Morning deadline
HKEX Deadline
2024-10-28
Noon deadline
Broker Results (T-2)
2024-10-29
Some brokers release in afternoon
Grey Market (T-1)
2024-10-30
Afternoon
HKEX Allotment (T-1)
2024-10-30
Evening
Registrar Allotment (T-1)
2024-10-30
Evening
Listing Day (T)
2024-10-31
First day of trading
Company Overview
| Stock Name | 华昊中天医药－Ｂ |
|---|---|
| Stock Code | 02563 |
| Company Full Name | 华昊中天医药－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 公司是由留美科學家團隊創立的國家級高新技術企業，依托先進且可持續的合成生物學新藥研發平臺，專注于開發具有自主知識產權的抗癌新藥，經過20余年的發展，公司已成為集新藥研發、生產和商業化為一體的整合型生物醫藥公司。 |
| Listing Date | 2024-10-31 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市北京經濟技術開發區亦城財富中心B座1202室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.biostar-pharm.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | 18A生物科技 |
|---|---|
| Offer Price | HK$ 16.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 76.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 28,009,600 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 3,200 |
| 2 lots | 400 | HK$ 6,400 |
| 3 lots | 600 | HK$ 9,600 |
| 4 lots | 800 | HK$ 12,800 |
| 5 lots | 1,000 | HK$ 16,000 |
| 6 lots | 1,200 | HK$ 19,200 |
| 7 lots | 1,400 | HK$ 22,400 |
| 8 lots | 1,600 | HK$ 25,600 |
| 9 lots | 1,800 | HK$ 28,800 |
| 10 lots | 2,000 | HK$ 32,000 |
| 15 lots | 3,000 | HK$ 48,000 |
| 20 lots | 4,000 | HK$ 64,000 |
| 25 lots | 5,000 | HK$ 80,000 |
| 30 lots | 6,000 | HK$ 96,000 |
| 35 lots | 7,000 | HK$ 112,000 |
| 40 lots | 8,000 | HK$ 128,000 |
| 45 lots | 9,000 | HK$ 144,000 |
| 50 lots | 10,000 | HK$ 160,000 |
| 100 lots | 20,000 | HK$ 320,000 |
| 150 lots | 30,000 | HK$ 480,000 |
| 200 lots | 40,000 | HK$ 640,000 |
| 250 lots | 50,000 | HK$ 800,000 |
| 300 lots | 60,000 | HK$ 960,000 |
| 350 lots | 70,000 | HK$ 1,120,000 |
| 400 lots | 80,000 | HK$ 1,280,000 |
| 450 lots | 90,000 | HK$ 1,440,000 |
| 500 lots | 100,000 | HK$ 1,600,000 |
| 750 lots | 150,000 | HK$ 2,400,000 |
| 1,000 lots | 200,000 | HK$ 3,200,000 |
| 1,250 lots | 250,000 | HK$ 4,000,000 |
| 1,500 lots | 300,000 | HK$ 4,800,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,000 lots | 400,000 | HK$ 6,400,000 |
| 2,250 lots | 450,000 | HK$ 7,200,000 |
| 2,500 lots | 500,000 | HK$ 8,000,000 |
| 2,750 lots | 550,000 | HK$ 8,800,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 20.8 |
|---|---|
| First Day Open | HK$ 21.5 |
| First Day Change | 30.00% |
| First Day Volume | 3185800.0 |
| First Day Turnover | 69538800.0 |
Use of Proceeds
| Use of Proceeds | 1、約44.9%或105.1百萬港元，將用于資助核心產品的進行中及計劃進行的臨床試驗； 2、約38.9%或91.1百萬港元，將用于資助核心產品以外的進行中及計劃進行的臨床試驗及產品臨床前研究以及核心產品研究者發起的試驗； 3、約3.0%或7.0百萬港元，將用于加強公司的國內商業化能力及建立公司的全球營銷網絡； 4、約3.2%或7.4百萬港元，將用于擴大產能； 5、約10.0%或23.4百萬港元，將用作營運資金及一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
建银国际金融有限公司 CE AJO225
中信建投（国际）融资有限公司 CE BAU112
Overall Coordinators (2)
建银国际金融有限公司 CE AJO225
中信建投（国际）融资有限公司 CE BAU112
Joint Bookrunners (16)
建银国际金融有限公司 CE AJO225
中信建投（国际）融资有限公司 CE BAU112
工银国际证券有限公司 CE ARO299
民银证券有限公司 CE APU820
浦银国际融资有限公司 CE BFZ375
中国银河国际证券（香港）有限公司 CE AXM459
申万宏源证券（香港）有限公司 CE AAC927
中泰国际证券有限公司 CE BAA855
东方证券（香港）有限公司 CE AVD362
复星国际证券有限公司 CE AAF432
GUOYUAN SECURITIES BROKERAGE (HONG KONG) LIMITED CE AOA594
山证国际证券有限公司 CE BEM330
第一上海证券有限公司 CE ABV488
百惠证券有限公司 CE BPQ161
MOUETTE SECURITIES COMPANY LIMITED CE BLE877
巨诚证券有限公司 CE BPX754
Joint Lead Managers (17)
建银国际金融有限公司 CE AJO225
中信建投（国际）融资有限公司 CE BAU112
工银国际证券有限公司 CE ARO299
民银证券有限公司 CE APU820
浦银国际融资有限公司 CE BFZ375
中国银河国际证券（香港）有限公司 CE AXM459
申万宏源证券（香港）有限公司 CE AAC927
中泰国际证券有限公司 CE BAA855
东方证券（香港）有限公司 CE AVD362
复星国际证券有限公司 CE AAF432
GUOYUAN SECURITIES BROKERAGE (HONG KONG) LIMITED CE AOA594
山证国际证券有限公司 CE BEM330
第一上海证券有限公司 CE ABV488
百惠证券有限公司 CE BPQ161
MOUETTE SECURITIES COMPANY LIMITED CE BLE877
巨诚证券有限公司 CE BPX754
富途证券国际（香港）有限公司 CE AZT137
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Novotech SG Holdings Pte. Ltd. | 23,081,600 HKD | — | 9.89% | — | 6 months | 2025-04-30 |
| 2 | Silky Water Absolute Return LPF | 61,555,200 HKD | — | 26.37% | — | 6 months | 2025-04-30 |
| 3 | 百洋健康产业国际商贸有限公司 | 15,376,000 HKD | — | 6.59% | — | 6 months | 2025-04-30 |
| 4 | 富策控股有限公司 | 77,721,600 HKD | — | 33.30% | — | 6 months | 2025-04-30 |
Directors & Management
| Chairman | 唐莉 |
|---|---|
| Company Secretary | 劉開林,陳奕斌 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Baygen QT Inc.(11.11%),珠海京蓉昊緣投資合伙企業(有限合伙)(5.59%),珠海華錦昊緣企業管理合伙企業(有限合伙)(5.27%) |
|---|
AI
AI Analysis
Market Sentiment
The IPO saw a moderate oversubscription of 21.45 times, reflecting steady but not frenzied demand. The overall hit rate of 27.47% is relatively high, indicating ample allocation for most applicants. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
A-tail applicants applying HKD 200,000 were allocated an expected 0.4444 lots, nearly identical to B-head applicants with HKD 250,000 who received 0.4615 lots, making the marginal benefit of the higher tier negligible. Given the clawback reallocation, this inefficiency suggests B-head may incur higher broker fees for minimal extra allocation. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
The demographic breakdown shows zero participants recorded for both mainland and Hong Kong categories, likely due to data limitations, so no regional or demographic trends can be inferred. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Subscription Tiers
IPO Timeline
